1616392-22-3
Chemical Structure
Pemrametostat
Synonym(s): GSK3326595; EPZ015938
- CAS No.: 1616392-22-3
- Formula:C24H32N6O3
- Molecular Weight:452.55
IUPAC Name: (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
InChIKey: JLCCNYVTIWRPIZ-NRFANRHFSA-N
SMILES: O=C(C)N1CCC(NC2=NC=NC(C(NC[C@H](O)CN3CCC(C=CC=C4)=C4C3)=O)=C2)CC1
Biological Activity: Pemrametostat (GSK3326595) is a protein arginine methyltransferase 5 (PRMT5) inhibitor. Pemrametostat decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. Pemrametostat can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pemrametostat | 99.82% | Pemrametostat (GSK3326595) is a protein arginine methyltransferase 5 (PRMT5) inhibitor. Pemrametostat decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. Pemrametostat can be used for research of relapsed/refractory mantle cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pemrametostat (Standard) | ≥98% | Pemrametostat (Standard) (GSK3326595 (Standard); EPZ015938 (Standard)) is the analytical standard of Pemrametostat (HY-101563). This product is intended for research and analytical applications. Pemrametostat (GSK3326595) is a protein arginine methyltransferase 5 (PRMT5) inhibitor. Pemrametostat decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. Pemrametostat can be used for research of relapsed/refractory mantle cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.85
HY-173562PRMT5 ligand 2 -
Similarity Score 0.80
HY-12727EPZ015666 -
Similarity Score 0.80
HY-173092PRMT5 ligand 1 -
Similarity Score 0.68
HY-100235AGSK591 hydrochloride -
Similarity Score 0.68
HY-181522PRMT5 ligand 3 -
Similarity Score 0.68
HY-100235RGSK591 (Standard) -
Similarity Score 0.66
HY-144188PRMT5-IN-17 -
Similarity Score 0.63
HY-144187PRMT5-IN-16 -
Similarity Score 0.56
HY-182820YZ-836P -
Explore the MedChemAI to find more analogs
References
- [1]. Che Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations [J]. Blood cancer journal, 2023, 13(1): 27. [Content Brief]
- [2]. Fedoriw A, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss [J]. Cancer cell, 2019, 36(1): 100-114. e25.
- [3]. Zhang Y, et al. PRMT5 inhibition induces pro‐inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice [J]. Journal of Cellular and Molecular Medicine, 2023, 27(8): 1056-1068.
- [4]. Li Z, et al. GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation [J]. Journal of Medical Virology, 2023, 95(1): e28158.
- [5]. Luo Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 Axis defines the tumorigenesis and immune response in hepatocellular carcinoma [J]. Hepatology, 2021, 74(4): 1932-1951. [Content Brief]
